These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 35138060)

  • 1. Risankizumab versus apremilast in the era of skin clearance.
    Veysey E
    Br J Dermatol; 2023 Nov; 189(6):e101-e102. PubMed ID: 37672670
    [No Abstract]   [Full Text] [Related]  

  • 2. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
    Ruggiero A; Picone V; Martora F; Fabbrocini G; Megna M
    Clin Cosmet Investig Dermatol; 2022; 15():1649-1658. PubMed ID: 35996400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W; Ghamrawi R; Haidari W; Feldman SR
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [No Abstract]   [Full Text] [Related]  

  • 6. Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series.
    Dawoud NM; El Badawy MB; Al Eid HS; Abdel Fattah MM
    Indian J Dermatol Venereol Leprol; 2022; 88(2):235-240. PubMed ID: 35138060
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on risankizumab for the treatment of moderate to severe psoriasis.
    Al-Janabi A; Warren RB
    Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
    McDonald J; Maliyar K; Gooderham MJ
    Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab in moderate-to-severe plaque psoriasis.
    Serrano L; Maloney V; Gordon KB
    Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.